Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Changes of intraocular cytokines including vascular endothelial growth factor (VEGF) will be
measured in recurrence of polypoidal choroidal vasculopathy (PCV) during treatment of
ranibizumab.